Neuropeptide systems as novel therapeutic targets for depression and anxiety disorders
Top Cited Papers
- 1 November 2003
- journal article
- review article
- Published by Elsevier BV in Trends in Pharmacological Sciences
- Vol. 24 (11), 580-588
- https://doi.org/10.1016/j.tips.2003.09.011
Abstract
No abstract availableKeywords
This publication has 81 references indexed in Scilit:
- The Corticotropin-Releasing Factor1Receptor Antagonist R121919 Attenuates the Behavioral and Endocrine Responses to StressThe Journal of pharmacology and experimental therapeutics, 2003
- Galanin GAL-R1 Receptor Null Mutant Mice Display Increased Anxiety-Like Behavior Specific to the Elevated Plus-MazeNeuropsychopharmacology, 2003
- Reduction of Hypothalamic Vasopressinergic Hyperdrive Contributes to Clinically Relevant Behavioral and Neuroendocrine Effects of Chronic Paroxetine Treatment in a Psychopathological Rat ModelNeuropsychopharmacology, 2002
- The Neuropeptide Y (NPY) Y1 Receptor Subtype Mediates NPY-induced Antidepressant-like Activity in the Mouse Forced Swimming TestNeuropsychopharmacology, 2002
- Brain Neuropeptide Υ (NPY) in Stress and Alcohol DependenceProgress in Neurobiology, 2002
- Dose Response of Arginine Vasopressin to the CCK-B Agonist PentagastrinNeuropsychopharmacology, 2001
- Anxiogenic-Like Action of Galanin after Intra-Amygdala Administration in the RatNeuropsychopharmacology, 1999
- Substance P is involved in the sensitization of the acoustic startle response by footshocks in ratsBehavioural Brain Research, 1994
- Coexistence of peptides and classical neurotransmittersTrends in Neurosciences, 1983
- Organization of Ovine Corticotropin-Releasing Factor Immunoreactive Cells and Fibers in the Rat Brain: An Immunohistochemical StudyNeuroendocrinology, 1983